NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the ‘trial and error’ approach to finding the right antidepressant
NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...